COMPANY:

OncoHelix

"OncoHelix...to announce its partnership with AstraZeneca Canada to deliver cutting-edge liquid biopsy testing for men with metastatic castration-resistant prostate cancer (mCRPC) who meet appropriate clinical criteria and live in provinces which lack public funding for this type of diagnostic test. Utilizing advanced genomic profiling, this test provides critical insights to physicians to guide targeted treatments and is being made available for a limited time in Canada through OncoHelix's clinically accredited lab. The initiative is made possible with the support of a collaboration between AstraZeneca and Merck."

"Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX platform technology, and OncoHelix, a leader in precision diagnostics, today announced their partnership to provide ClarityDX Prostate to healthcare providers and men in the Middle East...ClarityDX Prostate uses biological data, clinical information, and AI-powered learning models to generate a risk score for aggressive prostate cancer, marking a significant advancement in prostate cancer screening....OncoHelix provides advanced molecular diagnostics and immune profile testing to the Middle East and North Africa (MENA) region through OncoHelix-coLAB, a state-of-the-art laboratory within Burjeel Medical City, Abu Dhabi."